Video

Closing Out With KRAS and HER2 Advances in NSCLC

Author(s):

Joshua K. Sabari, MD,Nicholas C. Rohs, MD

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD; conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, conclude this series by discussing encouraging data and updates in non–small cell lung cancer treatment for patients who harbor KRAS and HER2 abnormalities.

Funding from Daiichi Sankyo/Content Independently Developed by OncLive


Related Videos
Balazs Halmos, MD; Nicholas C. Rohs, MD; Josh Sabari, MD
Josh Sabari, MD, of NYU Grossman School of Medicine
Reviewing the Year 2021 in Lung Cancer Treatment
Isabel Preeshagul, DO, MBS
Ashish Saxena, MD, PhD, and Catherine Ann Shu, MD
Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD
Jamie Chaft, MD, and Vamsidhar Velcheti, MD
Joshua K. Sabari, MD
Related Content